Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
优化针对罕见的预先存在的耐药突变的检测和干预措施
基本信息
- 批准号:10044004
- 负责人:
- 金额:$ 69.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-21 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:BehaviorBiological ModelsCase StudyCellsClinicalClinical ResearchClinical TreatmentCommunicable DiseasesConsensusCoupledCytomegalovirusDNA Sequence AlterationDataDetectionDiseaseDrug resistanceEarly DiagnosisEarly InterventionEarly treatmentEvolutionFailureGene FrequencyGenesGenetic DiseasesGraphHIVHIV/TBImmunotherapyInstitutionInterventionKnowledgeLeadMalignant NeoplasmsMethodsModelingMulti-Drug ResistanceMusMutationMutation DetectionOutputPatient-Focused OutcomesPatientsPharmaceutical PreparationsPilot ProjectsPopulationPrevalenceResistanceResolutionRewardsRiskSamplingSeriesTechnologyTestingTimeToxic effectTreatment EfficacyTreatment FailureTuberculosisVirusbasecost efficientdrug developmentexperiencegenetic evolutiongenetic variantimprovedmelanomamouse modelnovelpre-clinicalpressurepreventresistance mechanismresistance mutationtargeted treatmenttherapeutic effectivenesstherapy outcometumor
项目摘要
Abstract
Genetic mutations that cause drug failure are a major obstacle in many diseases including cancer, HIV,
cytomegalovirus, and tuberculosis. Therapy-induced selection for resistance-conferring aberrations can arise
either from new mutations or from those that pre-existed in a small subpopulation of the cells or viruses. This
latter idea of pre-existing subclonal drug resistance is highly understudied across diseases, and there is no
general clinical consensus on the best way to implement counter-resistance therapies. A large part of this is due
to technical difficulties in detecting the subpopulations at both sufficient resolution and high enough throughput.
Here, we leverage a novel high-sensitivity DNA mutation detection technology, multiplex blocker displacement
amplification, and melanoma as a model system to study subclonal drug resistance for multiple genes
inhundreds of pre-therapy patient samples. We will pair this clinical study with novel mouse models of subclonal
resistance to optimize risk-reward strategies for counter-resistance therapies. Our preliminary data from
melanoma patients are consistent with data from other cancers suggesting that very low allelic-frequency
subclonal resistance mutations could pre-exist in over a third of patients' tumors. Therefore, our overall approach
is aimed at determining how to best treat patients with potential subclonal resistance, first by improving mutation
detection in patients and second by determining which mutation-positive patients would most benefit from
optimally-timed counter-resistance interventions. Although we start with melanoma as a model system, our
approach will serve as a broadly-applicable blueprint for recognizing and overcoming pre-existing subclonal
resistance.
摘要
导致药物失效的基因突变是许多疾病的主要障碍,包括癌症、艾滋病毒、
巨细胞病毒和肺结核。治疗诱导的选择性耐药赋予畸变可能会出现
或者来自新的突变,或者来自那些在细胞或病毒的小亚群中预先存在的突变。这
后一种预先存在的亚克隆耐药性的观点在各种疾病中都没有得到充分的研究,
关于实施抗耐药疗法的最佳方式的普遍临床共识。其中很大一部分是由于
在以足够的分辨率和足够高的通量检测亚群方面存在技术困难。
在这里,我们利用一种新的高灵敏度的DNA突变检测技术,多重阻断剂置换
扩增和黑色素瘤作为模型系统,研究多个基因的亚克隆耐药性
数以百计的治疗前患者样本。我们将这项临床研究与新的亚克隆小鼠模型配对,
以优化抗耐药治疗的风险回报策略。我们的初步数据来自
黑色素瘤患者与其他癌症的数据一致,表明非常低的等位基因频率
亚克隆耐药突变可能预先存在于超过三分之一的患者肿瘤中。因此,我们的总体方法
旨在确定如何最好地治疗潜在亚克隆耐药患者,首先通过改善突变,
检测患者,其次通过确定哪些突变阳性患者将最受益于
最佳时机的抵抗干预。虽然我们以黑色素瘤作为模型系统开始,
方法将作为一个广泛适用的蓝图,认识和克服预先存在的亚克隆
阻力
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lawrence Kwong其他文献
Lawrence Kwong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lawrence Kwong', 18)}}的其他基金
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
优化针对罕见的预先存在的耐药突变的检测和干预措施
- 批准号:
10684107 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously
黑色素瘤中的汇聚节点可同时阻断多种致癌途径
- 批准号:
10189539 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously
黑色素瘤中的汇聚节点可同时阻断多种致癌途径
- 批准号:
10670767 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
优化针对罕见的预先存在的耐药突变的检测和干预措施
- 批准号:
10449299 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously
黑色素瘤中的汇聚节点可同时阻断多种致癌途径
- 批准号:
10028343 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously
黑色素瘤中的汇聚节点可同时阻断多种致癌途径
- 批准号:
10431861 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
优化针对罕见的预先存在的耐药突变的检测和干预措施
- 批准号:
10267170 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
相似海外基金
Nonlocal Variational Problems from Physical and Biological Models
物理和生物模型的非局部变分问题
- 批准号:
2306962 - 财政年份:2023
- 资助金额:
$ 69.09万 - 项目类别:
Standard Grant
Point-of-care optical spectroscopy platform and novel ratio-metric algorithms for rapid and systematic functional characterization of biological models in vivo
即时光学光谱平台和新颖的比率度量算法,可快速、系统地表征体内生物模型的功能
- 批准号:
10655174 - 财政年份:2023
- 资助金额:
$ 69.09万 - 项目类别:
Multi-scale stochastic systems motivated by biological models
由生物模型驱动的多尺度随机系统
- 批准号:
RGPIN-2015-06573 - 财政年份:2022
- 资助金额:
$ 69.09万 - 项目类别:
Discovery Grants Program - Individual
Micro-electrofluidic platforms for monitoring 3D human biological models
用于监测 3D 人体生物模型的微电流体平台
- 批准号:
DP220102872 - 财政年份:2022
- 资助金额:
$ 69.09万 - 项目类别:
Discovery Projects
Multi-scale stochastic systems motivated by biological models
由生物模型驱动的多尺度随机系统
- 批准号:
RGPIN-2015-06573 - 财政年份:2021
- 资助金额:
$ 69.09万 - 项目类别:
Discovery Grants Program - Individual
Multi-scale stochastic systems motivated by biological models
由生物模型驱动的多尺度随机系统
- 批准号:
RGPIN-2015-06573 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
Discovery Grants Program - Individual
Harnessing machine learning and cloud computing to test biological models of the role of white matter in human learning
利用机器学习和云计算来测试白质在人类学习中的作用的生物模型
- 批准号:
2004877 - 财政年份:2020
- 资助金额:
$ 69.09万 - 项目类别:
Fellowship Award
A Portable low-cost, Point of Investigation CapCell Scope to Image and Quantify the Major Axes of Metabolism and the Associated Vasculature in In vitro and In vivo Biological Models
便携式低成本调查点 CapCell 示波器,用于对体外和体内生物模型中的主要代谢轴和相关脉管系统进行成像和量化
- 批准号:
9899988 - 财政年份:2019
- 资助金额:
$ 69.09万 - 项目类别:
Multi-scale stochastic systems motivated by biological models
由生物模型驱动的多尺度随机系统
- 批准号:
RGPIN-2015-06573 - 财政年份:2019
- 资助金额:
$ 69.09万 - 项目类别:
Discovery Grants Program - Individual
A Portable low-cost, Point of Investigation CapCell Scope to Image and Quantify the Major Axes of Metabolism and the Associated Vasculature in In vitro and In vivo Biological Models
便携式低成本调查点 CapCell 示波器,用于对体外和体内生物模型中的主要代谢轴和相关脉管系统进行成像和量化
- 批准号:
9753458 - 财政年份:2019
- 资助金额:
$ 69.09万 - 项目类别: